Across the recent three months, 11 analysts have shared their insights on Hologic HOLX, expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 7 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 4 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Hologic, revealing an average target of $83.09, a high estimate of $90.00, and a low estimate of $70.00. Highlighting a 3.05% decrease, the current average has fallen from the previous average price target of $85.70.
Interpreting Analyst Ratings: A Closer Look
The standing of Hologic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Donnelly | Citigroup | Lowers | Neutral | $70.00 | $80.00 |
| Andrew Cooper | Raymond James | Lowers | Outperform | $90.00 | $95.00 |
| Conor McNamara | RBC Capital | Lowers | Sector Perform | $85.00 | $88.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $73.00 | $76.00 |
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $84.00 | $84.00 |
| Puneet Souda | Leerink Partners | Lowers | Market Perform | $75.00 | $80.00 |
| Mike Matson | Needham | Maintains | Hold | $90.00 | $90.00 |
| Tejas Savant | Morgan Stanley | Lowers | Equal-Weight | $82.00 | $84.00 |
| Mike Matson | Needham | Maintains | Buy | $90.00 | $90.00 |
| Mike Matson | Needham | Maintains | Buy | $90.00 | $90.00 |
| Tycho Peterson | Jefferies | Announces | Hold | $85.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Hologic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Hologic analyst ratings.
Delving into Hologic's Background
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Hologic: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Hologic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.86% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin excels beyond industry benchmarks, reaching 19.67%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hologic's ROE stands out, surpassing industry averages. With an impressive ROE of 4.06%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.25%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.53, Hologic adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
